SystImmune

Syst Immune

Biotechnology, Northeast 95th St, Redmond, Washington, 15318, United States, 11-50 Employees

systimmune.com

  • LinkedIn

phone no Phone Number: 14*********

Who is SYSTIMMUNE

Located in Redmond WA, founded in 2014, Systimmune Inc. is a bio-pharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and tri-specif...

Read More

map
  • 15318 Northeast 95th St, Redmond, Washington, United States Headquarters: 15318 Northeast 95th St, Redmond, Washington, United States
  • 2014 Date Founded: 2014
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $10 Million to $25 Million
  • tech-icon Active Tech Stack: See technologies
  • Yi Zhu CEO:   Yi Zhu

industries-icon Industry: Biotechnology

SIC SIC Code: 2834

checked-icon Does something look wrong? Fix it. | View contact records from SYSTIMMUNE

SystImmune Org Chart and Mapping

VP-Level

Fabio Mataveli

VP Clinical Development

Employees

Hai Zhu

Vice President of Biometrics, Assistant to CEO

Sarah Rickli

Associate Scientist and Research Coordinator

Dennis Goulet

Principal Scientist, Head of Protein Engineering

Rachel Shepherd

Upstream Processing Scientist

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding SystImmune

Answer: SystImmune's headquarters are located at Northeast 95th St, Redmond, Washington, 15318, United States

Answer: SystImmune's phone number is 14*********

Answer: SystImmune's official website is https://systimmune.com

Answer: SystImmune's revenue is $10 Million to $25 Million

Answer: SystImmune's SIC: 2834

Answer: SystImmune has 11-50 employees

Answer: SystImmune is in Biotechnology

Answer: SystImmune contact info: Phone number: 14********* Website: https://systimmune.com

Answer: Located in Redmond WA, founded in 2014, Systimmune Inc. is a bio-pharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and tri-specific antibodies, as well as antibody-drug conjugates (ADC's). Our objective is to create biologics that work through systematic intervention on the solid tumor micro-environment, to either directly attack the tumor and/or to activate the immune system to attack the tumor. We are a group of highly experienced immuno-oncology scientists utilizing several technology platforms to develop world class advanced antibody-based drug therapies.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access